IN-DEPTH REVIEW

Hidradenitis Suppurativa and Down Syndrome: Systematic Review and Meta-Analysis

Niyaz Mostafa, MD1,2, Kevin Phan, MD1,2,3, Tajrian Amin, MD1, Saxon D. Smith, MBChB, PhD4

1 Faculty of Medicine, University of New South Wales (UNSW), Sydney, Australia
2 St. George Dermatology and Skin Cancer Centre, Kogarah, Australia
3 Department of Dermatology, Liverpool Hospital, Sydney, Australia
4 The Dermatology and Skin Centre, Gosford, Australia

ABSTRACT

Introduction: Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease, characterized by the presence of painful lesions and recurrent abscesses, and nodules. These lesions can later rupture to form sinus tracts and fistulas. The exact etiology of HS is currently unknown, however a link between genetic, social and environmental factors has been postulated in recent studies. A number of studies have shown a significant association between HS and down syndrome (DS), however the relationship between HS and DS is unclear. We conducted a systematic review and meta-analysis to test for any association between HS and down syndrome.

Methods: A systematic review of existing studies was performed and data was pooled for meta-analysis. Reviews, abstracts and case reports were excluded. Eligible studies were those which investigated HS in cases of down syndrome. Studies that reported DS cases amongst HS patients were not included in the present study.

Results: A total of 6 studies were identified from systematic database searches after applying inclusion and exclusion criteria. Pooled meta-analysis demonstrated a significant association between HS and down syndrome. The pooled proportion of HS cases in the DS group was 10.9% (95% CI, 3.8%-27.6%). The pooled proportion of HS cases in the control group was 0.4% (95% CI, 0.2%-0.8%). This difference was significantly different (P<0.001). The odds ratio is 12.02(95% CI 10.91-13.23).

Conclusion: The evidence for hidradenitis suppurativa being associated with down syndrome is very limited. The data is promising however, and further prospective studies with larger cohorts are required to reaffirm the findings in the present review.

INTRODUCTION

Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease that affects 1-4% of the population1-3. It is characterized by the presence of painful lesions and recurrent abscesses, and nodules affecting the skin. These lesions can later rupture to form sinus tracts and fistulas. HS is a progressive disease that is debilitating and can impact an individual across physical, social and emotional domains, which is worsened in the absence of adequate management. The exact etiology of HS is currently unknown, however a link between genetic, social and environmental factors has been postulated in recent studies1-3.

Down syndrome, also known as trisomy 21, is one of the most common chromosomal disorders affecting chromosome 21. It presents with a number of features in affected patients including, intellectual
disability, congenital heart disease as well as other diseases involving different systems of the body. DS affects between 1 in 400-1500 babies born across different populations, which varies according to maternal age and screening schedules in the prenatal period.

There is an increased prevalence of mucocutaneous disorders amongst DS patients in comparison to the general population source. A number of studies have shown a significant association between HS and Down syndrome (DS), however the relationship between HS and DS is unclear. We conducted a systematic review and meta-analysis to test for any association between HS and Down syndrome.

**Search strategy**

We performed a systematic review and meta-analysis in accordance to the recommended Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The search was performed in 2021 and Electronic searches were performed using Ovid Medline, PubMed, Cochrane Central Register of Controlled Trials (CCTR), Cochrane Database of Systematic Reviews (CDSR), ACP Journal Club, and Database of Abstracts of Review of Effectiveness (DARE) from their dates of inception to August 2021. Search terms included: “hidradenitis suppurativa”, “hidradenitis suppurative”, “acne inversa”, “velpeau”, “verneuil” combined with “Down syndrome” or “trisomy 21”. The resulting articles were assessed systematically by two independent reviewers using the inclusion and exclusion criteria.

**Selection Criteria**

All eligible studies included those investigating the presence of HS in a population of Down syndrome patients. Studies that reported DS cases amongst HS patients were not included in the present study. All studies must have included either the proportion of patients with HS in each group or the summary effect size for association between HS and DS.

**Data extraction and quality assessment**

The data was extracted by two independent reviewers from articles text, tables and figures. The data of interest included study type, location, demographic data and information related to the proportion of patients with HS in a DS patient population. The quality of the studies was assessed using the Newcastle-Ottawa scale.

**Statistical Analysis**

Firstly, to establish variance of raw proportions, a logit proportion transformation was applied. To incorporate heterogeneity (anticipated among the included studies), transformed proportions were combined using DerSimonian-Laird random effects models. Finally the pooled estimates were back-transformed. Heterogeneity was evaluated using Cochran Q and I² test. Meta-regression based on subgroup (Down syndrome versus controls) was performed. All analyses were performed using the metafor package for R version 3. P values <0.05 were considered statistically significant.

**RESULTS**

A total of 30 studies were identified from the electronic database search. After applying inclusion and exclusion criteria, six studies were included for the present systematic review and meta-analysis (Figure 1).
Study Characteristics

Study characteristics and demographic data are summarized in Table 1. Four studies were retrospective and observational in nature\(^7,9\)–\(^\text{11}\), whereas the other 2 included studies were case-control studies\(^8,12\). Three studies reported age ranges\(^8,\text{10,11}\) and only Garg et al.\(^8\) adjusted their statistical analysis for confounding factors.

Assessment of study bias

The risk of bias in this study was evaluated using the Newcastle Ottawa scale for cohort and cross-sectional studies. The results are summarized in Table 1. A majority of studies scored 7 or higher, indicating a low level of bias amongst the studies.

Association between HS and DS

Pooled meta-analysis demonstrated a significant association between HS and Down syndrome (Figure 1). The pooled proportion of HS cases in the DS group was 10.9% (95% CI, 3.8%-27.6%). The pooled proportion of HS cases in the control group was 0.4% (95% CI, 0.2%-0.8%). This difference was significantly different (P<0.001). The odds ratio is 12.02 (95% CI 10.91-13.23).

Table 1. Study Characteristics

From the present meta-analysis and systematic review of observational and case-control studies, we demonstrated a significant association between HS and Down syndrome. Our findings add to the limited, but expanding body of literature that HS and other follicular disorders may be associated with DS. Treating clinicians should be aware of the potential link between these 2 conditions in order to institute early intervention in future DS patients.

The exact etiology of HS in DS remains unclear, however our findings suggests that there may be some form of genetic predisposition to HS in Down syndrome patients as postulated in other studies\(^13\). The link between HS and DS may be related to the increased expression of amyloid precursor protein (APP), normally encoded by a gene located on chromosome 21\(^14\). In DS patients, cleavage of APP by gamma-secretase leads to the formation of beta-amyloid plaques. The presence of the plaques leads to patients developing Alzheimer's disease earlier in life compared to the general population. APP also plays a role in the epidermis, particularly in stimulating the adhesion, migration and proliferation of keratinocytes\(^15\). Increased APP in DS patients may cause the hyperproliferation of keratinocytes and plugging of follicles, which is seen histopathologically as features in HS. Gamma-secretase contributes to this theory, in familial HS, functional mutations of genes encoding the gamma-secretase protein complex have been observed\(^16\). Mutations in gamma-secretase and increased APP in DS may also lead to a defective notch signalling pathway and altered pro-inflammatory effects down the line\(^13,17\). This includes inadequate suppression of the innate immune system, causing inflammation, a hallmark of HS, as well as the inhibition of natural killer cell activity. Another potential link between HS and DS is the shared comorbidity of obesity. There are
<table>
<thead>
<tr>
<th>Study</th>
<th>Location</th>
<th>Design</th>
<th>Cases/Controls</th>
<th>Females % (cases/control)</th>
<th>Age in years (cases/control)</th>
<th>Adjustment</th>
<th>NOS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Firsowicz et al., Pediatr Dermatol, 2020</td>
<td>USA</td>
<td>Retrospective observational</td>
<td>243/0</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>7</td>
</tr>
<tr>
<td>Garg et al., Br J Dermatol, 2018</td>
<td>USA</td>
<td>Case-control</td>
<td>11936/1681/3290</td>
<td>60/44</td>
<td>18-29</td>
<td>36/18</td>
<td>Down syndrome, age, sex, race, obesity</td>
</tr>
<tr>
<td>Hamadah et al., Pediatr Dermatol, 2017</td>
<td>Saudi Arabia</td>
<td>Retrospective observational</td>
<td>29/0</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>7</td>
</tr>
<tr>
<td>Poizeau et al., Acta Derm Venereol, 2019</td>
<td>France</td>
<td>Retrospective observational</td>
<td>783/0</td>
<td>46/0</td>
<td>HS</td>
<td>Non-HS</td>
<td>NA</td>
</tr>
<tr>
<td>Rork et al., Pediatr Dermatol, 2020</td>
<td>USA</td>
<td>Retrospective observational</td>
<td>101/0</td>
<td>39/0</td>
<td>23 (10-53)/0²</td>
<td>31 (9-67)/0³</td>
<td>NA</td>
</tr>
<tr>
<td>Sechi et al., Dermatol Pract Concept, 2019</td>
<td>Italy</td>
<td>Case-control</td>
<td>131/12351</td>
<td>42/38</td>
<td>19.7 (15.9)/0³</td>
<td>NA</td>
<td>6</td>
</tr>
</tbody>
</table>

NA, not reported; NOS, Newcastle-Ottawa scale for study quality; 1, age reported as means in different age groups; 2, age reported as median and range; 3, age reported as mean and standard deviation.

**Figure 1. PRISMA flowchart**
increased frequencies of obesity in children with DS in comparison to healthy children\textsuperscript{18}. This common comorbidity between both diseases may mean that obesity in patients with DS may predispose them to HS\textsuperscript{19,20}.

HS is also associated with several other comorbidities including smoking, dyslipidaemia, diabetes mellitus and metabolic syndrome\textsuperscript{3} as well as those associated with the integumentary system such as acne and pilonidal disease\textsuperscript{21}. Recent evidence based recommendations from the US and Canadian HS foundations suggest regular screening for such comorbidities as well as screening DS patients for HS\textsuperscript{22}. The decision to screen for certain diseases should vary based on patient risk factors.

The present review has several limitations. The studies included were composed of both case-control and observational studies, which were mostly retrospective, making them susceptible to selection and assessment bias. Confounder variables may have influenced the analysed effect sizes, which were unadjusted. Data for a majority of studies was obtained from large databases which may have errors in coding disease parameters, and there is likely heterogeneity between the criteria used for HS and Down syndrome diagnosis. Prospective studies with larger cohorts are required to reaffirm the findings in the present review.

Pooled analysis of existing studies reveals that patients with DS are associated with an increased risk of HS in comparison to controls. Dermatologists and other clinicians involved in the care of patients with DS should be aware of this association and implement early screening and intervention based on risk factors in this cohort.

\textbf{Conflict of Interest Disclosures:} None

\textbf{Funding:} None

\textbf{Corresponding Author:} Niyaz Mostafa
University of New South Wales
Faculty of Medicine
Sydney, Australia, 2052
Email: nmostafa.research@gmail.com

\textbf{References:}
1. Vekic DA, Frew J, Cains GD. Hidradenitis suppurativa, a review of pathogenesis, associations


